CD274 and non-small cell lung carcinoma: The Pembrolizumab versus Docetaxel trial (2015) involving 1034 patients with advanced NSCLC found that Pembrolizumab significantly improved OS and PFS compared to Docetaxel, particularly in patients with high PD-L1 expression, with fewer grade 3–5 adverse events [79].